LDL cholesterol, apolipoprotein B, lipoprotein(a), apolipoprotein CIII and triglyceride lowering by MGL-3196, a thyroid hormone beta selective agonist, in a 12 week study in HeFH patients
28 August 2018 (08:30 - 12:30)
Organised by:
Abstract
Slides
About the speaker
Madrigal Pharmaceuticals, Conshohocken (United States of America)
20 More presentations in this session
Access the full session
The Event
ESC Congress 2018
28 August 2018
08:30 CET
